Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Embracing China 2.0: AZ, Merck KGaA Set Up Funds, J&J Steps Up Digital Push

Executive Summary

AstraZeneca has pledged $1bn to a healthcare fund to support local innovation in China, joining big pharma peers J&J and Merck KGaA in fresh moves to embrace this market, where a new wave of digital technology transformation and fast-shifting trends now favor novel new therapies and the rise of local health start-ups

You may also be interested in...



China 'Bay Area' Calling: Merck KgAA Chooses Guangzhou For New Innovation Center

Thinking all about scale, China opens the world’s longest sea bridge linking the Pearl River Delta area with Hong Kong and Macao, and the newly-formed 'Bay Area' is already attracting drug makers to look further afield than the traditional Beijing and Shanghai locations.

China's Ongoing 'COVID Zero' Policies To Prompt More Domestic Deals?

China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.

US-China Decoupling Gets On Biotech's Nerves

The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC126156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel